Can Breast Cancer Previvors Safely Use HRT?

A woman tells her doctor she skips mammograms because nobody in her family has ever had breast cancer. It sounds like sound reasoning. It is also wrong, most of the time. Only 5 to 10 percent of breast cancers come from an inherited gene mutation (02:03). The rest show up in women with no family history at all, which is exactly the gap that worries oncologist Dr. Eleonora Teplinsky, author of the book Beyond the Pink, in the second half of her conversation with Dr. Mary Claire Haver on the podcast unPAUSED.

Family history still matters, Teplinsky says, but it needs translation. A grandmother diagnosed at 85 is a very different signal than five relatives diagnosed before 50 (01:00). The second pattern points toward a hereditary cancer syndrome, something genetic testing can confirm. The first is closer to ordinary aging. Teplinsky's broader point is that breast cancer risk assessment is not a family story. It is a calculation, and it should start at age 25 (02:53), using tools like the Tyrer-Cuzick model, a free online questionnaire that factors in menstrual history, family history, and breast density to estimate a woman's chance of developing breast cancer over her lifetime. A result of 20 percent or higher moves a woman into the high-risk category, which usually means supplementing a mammogram with MRI or ultrasound (03:31).

The Myth That Protects No One

Density turns out to be a double problem, not a single one. Many women assume dense breast tissue simply hides tumors on a mammogram, the way a flashlight struggles to find something white in a white room. Teplinsky corrects that assumption directly.

"Both. Wow. Mm-hmm. And we don't entirely know how dense breasts increase breast cancer risk. There's a lot of research going on, but it's both." — Dr. Eleonora Teplinsky [12:14]

Roughly half of women have dense breast tissue, and about 10 percent fall into the densest category, called Category D (13:22). For that group, Teplinsky recommends adding an MRI, though current guidelines do not yet mandate it broadly. She is candid about the limits of her own favorite model. The Tyrer-Cuzick tool replaced the older Gail model specifically because it accounts for density, yet it can also overestimate a woman's actual risk (10:47). A newer AI tool called Clariti is being piloted in Massachusetts to estimate five-year risk directly from a mammogram image, with coverage guidelines now recommending it starting at age 35 (11:34). None of this, Teplinsky warns, should be confused with direct-to-consumer blood tests like Galleri, which look for a cancer signal in a vial of blood. Those tests can produce false positives and false negatives and often miss early cancers confined to breast tissue. "They should not replace screening," she says, naming mammograms, colonoscopies, and Pap smears as the proven baseline (09:18).

For women who do carry a mutation such as BRCA, CHEK2, ATM, or PALB2 (05:12), the numbers shift dramatically. A BRCA mutation carries up to an 80 percent lifetime risk of breast cancer, high enough that doctors typically discuss risk-reducing mastectomy, though that calculus changes after age 65 (07:12). It is a conversation, Teplinsky stresses, not an automatic verdict, and one she says should include people of color more often than it currently does. Most genetic testing databases were built on Eastern European ancestry data, which means women of color are more likely to receive an ambiguous result called a variant of uncertain significance, a genetic change whose effect on cancer risk simply is not known yet (20:25). And a negative test does not erase risk if close relatives were never tested themselves. Family history, even without a known mutation, still raises risk above average (21:21).

Nowhere does the fear outpace the evidence more than around hormones. Teplinsky describes a 38-year-old BRCA carrier who removes her ovaries to cut ovarian cancer risk but keeps her breast tissue intact, a status called previvor, someone who carries high cancer risk but has never had a diagnosis (14:16). The old assumption was that any brush with elevated breast cancer risk meant lifetime estrogen avoidance.

"But here's the thing. Previvors can absolutely use hormone replacement therapy." — Dr. Eleonora Teplinsky [15:04]

She points to a recent study by researcher JoAnn Katsopoulos that followed more than 600 previvors who used hormone therapy after ovary removal against more than 600 who did not. Women on estrogen alone actually had a lower breast cancer risk than those not on hormones. Women on estrogen plus a progestogen had equal risk, not elevated risk (15:46). That distinction between "equal" and "protective" is new information, and it matters because premature surgical menopause before age 45 raises cardiovascular, cognitive, and musculoskeletal risk on its own (19:06).

The Body After Treatment

Cancer treatment does not end when the chemotherapy port comes out. Teplinsky walks through a chain of consequences that rarely gets explained up front. Chemotherapy-induced ovarian failure can drop lumbar spine bone density by 4 percent within six months, a finding first published by researcher Shapiro in 2001, and aromatase inhibitors, a class of drugs that block estrogen production, add another 2 percent loss per year on top of that (21:46). Her response is procedural: everyone who receives chemotherapy is eligible for a baseline bone density scan, not only people on hormone-blocking drugs, because chemotherapy alone can cause bone and muscle loss (22:20). She usually orders the $99 scan after chemotherapy ends rather than before, since insurance rarely covers both.

"If you've had chemo, you should also be getting a baseline bone density." — Dr. Eleonora Teplinsky [23:36]

The heart carries its own hidden bill. A 2013 study in the New England Journal of Medicine by researcher Darby found major coronary events rose about 7.5 percent after radiation treatment for breast cancer, largely because the breast sits directly in front of the heart (27:37). Radiation oncologists now use a technique called the deep inspiratory breath hold, which has patients breathe in a specific way during left-sided radiation to physically move the heart out of the beam's path (28:00). Chemotherapy drugs, premature menopause, and aromatase inhibitors can each affect cholesterol independently, which is why Teplinsky urges survivors to ask their medical team directly whether a cardio-oncologist should be monitoring them.

Cognition gets less structured support. What patients call "chemo brain" is formally known as cancer-related cognitive impairment, and it often escapes detection because standard cognitive tests are built to catch dementia, not the subtler slowdown a high-functioning professional might notice in her own work (25:06). There is no diagnostic code for it. The same holds for the psychological aftermath of surgery. Teplinsky describes a technique called the mirror program, in which patients reintroduce themselves to their post-mastectomy bodies gradually, starting with a small mirror before facing a full-length one (32:04), a small act of pacing meant to replace a surprise with a plan.

What ties the whole conversation together is a shift from fear to information. Teplinsky's closing advice is almost administrative: write down current side effects, write down long-term worries, and bring both lists to the next appointment (34:05). It is a modest request, built on a simple premise, that nobody should be told no without first being told why, or what the alternative actually is.